Biocon Limited (BIOCON)
ISIN: - Industry: Biotechnology Sector: Healthcare Website
320.15
-0.85(-0.26%)

Biocon Limited, a biopharmaceutical company, manufactures pharmaceuticals, and medicinal chemical and botanical products. The company operates through Generics, Novel Biologics, Biosimilars, and Research Services segments. It focuses in the areas of diabetes, oncology, immunology, dermatology, ophthalmology, neurology, rheumatology, and inflammatory diseases. It is also involved in the integrated discovery, development, and manufacturing services for small and large molecules, antibody-drug conjugates, and oligonucleotides. The company serves customers in approximately 120 countries. Biocon Limited was founded in 1978 and is headquartered in Bengaluru, India.

Pricing Updates

TODAY'S HIGH

324.1

TODAY'S LOW

318.5

52 WEEK HIGH

414.4

52 WEEK LOW

305

Major Holders

% of Shares Held by
All Insider

65.58%

% of Shares Held by
Institutions

15.42%

% of Float Held by
Institutions

44.82%

Number of Institutions
Holding Shares

124

Company Overview

MARKET CAP

38455.45 Cr.

ETERPRISE VALUE

40625.41 Cr.

NO. OF SHARES

120.06 Cr.

BOOK VALUE

70.683

DIV. YIELD

0.5%

DEBT

5146.59 Cr.

GROSS PROFIT

5465.60 Cr.

CASH

2965.20 Cr.

REVENUE

8183.99 Cr.

REVENUE/SHARE

68.663

OHLC Chart 1y 2y 5y 10y

Price Chart

1d 1w 1m 3m 6m 1Yr 2Yr 5Yr

Volumes Chart

1d 1w 1m 3m 6m 1Yr 2Yr 5Yr

Cashflows

ParticularsMar 2022Mar 2021Mar 2020Mar 2019
Investments231.40 Cr.-1851.20 Cr.174.40 Cr.295.50 Cr.
Change To Liabilities161.80 Cr.310.20 Cr.406.70 Cr.608.30 Cr.
Total cashflows from Investing Activities-1699.10 Cr.-3624.70 Cr.-1558.90 Cr.-713.80 Cr.
Net Borrowings309.20 Cr.1882.30 Cr.12.60 Cr.7.50 Cr.
Total Cash from Financing Activities242.10 Cr.2564 Cr.387.60 Cr.-241.70 Cr.
Other Liabilities-63.70 Cr.-216.20 Cr.-355.60 Cr.-107.90 Cr.
Total Assets42.80 Cr.40.70 Cr.31.80 Cr.31.70 Cr.
Net Income648.40 Cr.740.50 Cr.748.20 Cr.905.30 Cr.
Change in Cash-243.30 Cr.72.30 Cr.165.40 Cr.210.30 Cr.
Effect of Exchange Rate3.30 Cr.7.10 Cr.53.60 Cr.11.20 Cr.
Total Cash from Operating Activities1176.60 Cr.1159.70 Cr.1283.10 Cr.1154.60 Cr.
Depreciation814.20 Cr.710.70 Cr.550.10 Cr.445.70 Cr.
Other Cashflows from Investing Activities-7.80 Cr.65.20 Cr.96.10 Cr.79.40 Cr.
Dividends Paid00-63 Cr.-72.20 Cr.
Change to Inventory-414 Cr.-445.40 Cr.-380.60 Cr.-305.20 Cr.
Change to Account Receivables-473.60 Cr.-72.40 Cr.164.40 Cr.-224.30 Cr.
Other Cashflows from Financing Activities-109.60 Cr.650.30 Cr.435.50 Cr.-107.80 Cr.
Change to Net Income503.50 Cr.127.90 Cr.147.80 Cr.-169.40 Cr.
Capital Expenditures-1697.80 Cr.-1516.90 Cr.-1604.20 Cr.-1222.10 Cr.

Financials

ParticularsMar 2022Mar 2021Mar 2020Mar 2019
Research Development-476.40 Cr.-350.70 Cr.-345.80 Cr.-269.90 Cr.
Effect of Accounting ChargesNoneNoneNoneNone
Income Before Tax983.10 Cr.1077.40 Cr.1214.90 Cr.1214.90 Cr.
Minority Interest1037.50 Cr.880.70 Cr.677.30 Cr.608.90 Cr.
Net Income1156 Cr.953.70 Cr.1052 Cr.945.90 Cr.
Selling General Administrative1880.10 Cr.1902.60 Cr.1654.40 Cr.1165.30 Cr.
Gross Profit5465.60 Cr.4484.80 Cr.3983.50 Cr.3617.80 Cr.
Ebit1156 Cr.953.70 Cr.1052 Cr.945.90 Cr.
Operating Income1156 Cr.953.70 Cr.1052 Cr.945.90 Cr.
Other Operating Expenses2091.70 Cr.1262.40 Cr.1070.60 Cr.1328.70 Cr.
Interest Expense-67.60 Cr.-57.70 Cr.-64.90 Cr.-70.90 Cr.
Extraordinary ItemsNoneNoneNoneNone
Non RecurringNoneNoneNoneNone
Other ItemsNoneNoneNoneNone
Income Tax Expense211.50 Cr.221.50 Cr.315.10 Cr.212.30 Cr.
Total Revenue8184 Cr.7105.80 Cr.6300.50 Cr.5514.40 Cr.
Total Operating Expenses7028 Cr.6152.10 Cr.5248.50 Cr.4568.50 Cr.
Cost of Revenue2718.40 Cr.2621 Cr.2317 Cr.1896.60 Cr.
Total Other Income Expense Net-172.90 Cr.123.70 Cr.162.90 Cr.269 Cr.
Discontinued Operations0-9.70 Cr.-28.90 Cr.-28.90 Cr.
Net Income from Continuous Ops.771.60 Cr.855.90 Cr.899.80 Cr.1002.60 Cr.
Net Income Applicable to Common Shares648.40 Cr.740.50 Cr.748.20 Cr.905.30 Cr.

Balance Sheet

ParticularsMar 2022Mar 2021Mar 2020Mar 2019
Intangible Assets1288.70 Cr.1173.60 Cr.1042.70 Cr.803.90 Cr.
Capital Surplus061.90 Cr.23.80 Cr.117.10 Cr.
Total Liabilities10924 Cr.10014.70 Cr.7060.70 Cr.5485.50 Cr.
Stock Holder Equity8432.50 Cr.7626.90 Cr.6705.80 Cr.6098 Cr.
Minority Interest1037.50 Cr.880.70 Cr.677.30 Cr.608.90 Cr.
Other Liabilities1292.90 Cr.1124.90 Cr.1125.70 Cr.812.40 Cr.
Total Assets20394 Cr.18522.30 Cr.14443.80 Cr.12192.40 Cr.
Common Stock600.30 Cr.600 Cr.600 Cr.300 Cr.
Retained Earnings06397.50 Cr.6075.80 Cr.5554.80 Cr.
Other Liabilities2876 Cr.2728.90 Cr.1747.40 Cr.906.30 Cr.
Good Will26.40 Cr.26.40 Cr.26.40 Cr.26.40 Cr.
Treasury Stock7832.20 Cr.567.50 Cr.6.20 Cr.126.10 Cr.
Other Assets962.10 Cr.875.70 Cr.843.20 Cr.751.50 Cr.
Cash1747.50 Cr.953.10 Cr.910.10 Cr.729.80 Cr.
Current Liabilities3828 Cr.4210.10 Cr.4008 Cr.3038.50 Cr.
Long Term Asset Charges293.30 Cr.307.70 Cr.368 Cr.324.70 Cr.
Short Long Term Debt905.50 Cr.802.80 Cr.735.60 Cr.620.20 Cr.
Other Stockholder Equity7832.20 Cr.701.80 Cr.140.70 Cr.240.50 Cr.
Property Plant Equipment9364.30 Cr.7964.10 Cr.7098 Cr.5539.60 Cr.
Total Cur. Assets8382.30 Cr.7600.40 Cr.5325 Cr.4888.50 Cr.
Long Term Investments370.20 Cr.882.10 Cr.108.50 Cr.182.50 Cr.
Net Tangible Assets7117.40 Cr.6426.90 Cr.5636.70 Cr.5267.70 Cr.
Short Term Investments1217.70 Cr.1647 Cr.889.50 Cr.1037.10 Cr.
Net Receivables2125.30 Cr.2016.80 Cr.1679 Cr.1678.40 Cr.
Long Term Debt3998.50 Cr.2961.60 Cr.1222.20 Cr.1525.60 Cr.
Inventory2298.20 Cr.1866.60 Cr.1435.90 Cr.1031.60 Cr.
Accounts Payable1608.50 Cr.1513.90 Cr.1325.10 Cr.1198.30 Cr.

New Offers


Upstox offer
Upstox

Open a demat account through us and get the account opening charges waived off

open paperless account